Optimizing Drug Therapy Safety of Geriatric Orthopedic Patients by Providing Integrated Geriatric Care-Advances in Geriatric Medicine and Research-CSCIED科技核心评价数据库-手机版

Optimizing Drug Therapy Safety of Geriatric Orthopedic Patients by Providing Integrated Geriatric Care

Optimizing Drug Therapy Safety of Geriatric Orthopedic Patients by Providing Integrated Geriatric Care

ES评分 0 浏览量：270 下载量：0

DOI	10.20900/agmr20250004
刊名	Advances in Geriatric Medicine and Research AGMR
年，卷(期)	2025, 7(1)
作者	Marcel Hoellger,Michael Kehrer,Dieter Christian Wirtz,Hendrik Kohlhof*,
作者单位	Clinic for Orthopedics and Trauma Surgery, University Bonn, Bonn 53127, Germany ; St. Antonius Hospital Cologne, Cologne 50968, Germany ;
摘要	Demographic change, accompanied by its complex requirements, represents a major challenge for today’s orthopedics and traumatology departments. The “geriatric patient”, is moving into focus, and increasingly requires geriatric-internal co-treatment in addition to orthopedic-injury surgery expertise. This retrospective case–control study investigated how the co-treatment by a geriatrician in orthopedic patients influences drug prescriptions, and whether and how an improvement in drug safety and more adequate pharmacotherapy can be achieved. The FORTA list established for the German-speaking region was used as the evaluation standard. Therefore, FORTA AB resulted from the total sum of the respective admissions or discharge medications, minus the FORTA-C and D hits. For the study, the FORTA categories C and D listed medications were considered particularly relevant because they are high-risk, and they were statistically reviewed during the study. A total of 54 patients in the study group (GOKM group) were treated according to the integrated geriatric orthopedic concept, compared to 59 patients in the reference group (OM group). In order to precisely test for an analysis of variance was performed with a mixed-design analysis of variance (ANOVA).
Abstract	Demographic change, accompanied by its complex requirements, represents a major challenge for today’s orthopedics and traumatology departments. The “geriatric patient”, is moving into focus, and increasingly requires geriatric-internal co-treatment in addition to orthopedic-injury surgery expertise. This retrospective case–control study investigated how the co-treatment by a geriatrician in orthopedic patients influences drug prescriptions, and whether and how an improvement in drug safety and more adequate pharmacotherapy can be achieved. The FORTA list established for the German-speaking region was used as the evaluation standard. Therefore, FORTA AB resulted from the total sum of the respective admissions or discharge medications, minus the FORTA-C and D hits. For the study, the FORTA categories C and D listed medications were considered particularly relevant because they are high-risk, and they were statistically reviewed during the study. A total of 54 patients in the study group (GOKM group) were treated according to the integrated geriatric orthopedic concept, compared to 59 patients in the reference group (OM group). In order to precisely test for an analysis of variance was performed with a mixed-design analysis of variance (ANOVA).
关键词	comanagement; geriatric medicine; orthopedic surgery; polypharmacy; potential inappropriate medication; clinical pharmacology; geriatric patient
KeyWord	comanagement; geriatric medicine; orthopedic surgery; polypharmacy; potential inappropriate medication; clinical pharmacology; geriatric patient
基金项目
页码	-

参考文献
相关文献

1.Statistisches Bundesamt. Bevölkerung Deutschlands bis 2050, 11. Koordinierte Bevölkerungsvorausberechnung
[Population of Germany until 2050, 11th Coordinated Population Projection]. Available from: www.destatis.de. Accessed on 27 Sep 2022. German.

2.Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516-23.

3.Van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998;51(5):367-75.

4.Schnurrer JU, Frölich JC. Zur Häufigkeit und Vermeidbarkeit von tödlichen unerwünschten Arzneimittelwirkungen
[On the frequency and preventability of fatal adverse drug reactions]. Der Internist. 2003;44(9):889-95. German.

5.Bikowski RM, Ripsin CM, Lorraine VL. Physician-patient congruence regarding medication regimens. J Am Geriatr Soc. 2001;49(10):1353-7.

6.Jörgensen T, Johansson S, Kennerfalk A, Wallander MA, Svärdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35(9):1004-9.

7.Eckardt R, Steinhagen-Thiessen E, Kämpfe S, Buchmann N. Polypharmazie und Arzneimitteltherapiesicherheit im Alter. Strategien zur Verbesserung
[Polypharmacy and medication safety in old age. Strategies for improvement]. Z Fur Gerontol Und Geriatr. 2014;47(4):293-301. German.

8.Hofmann W. Kritischer Einsatz von Medikamenten bei Demenz
[Critical use of medication in dementia]. Hamburg (Germany): Behrs’-Verlag; 2009. German.

9.Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337-44.

10.Lazarou J. Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-5.

11.Schurig A, Böhme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B, et al. Unerwünschte Arzneimittelwirkungen (UAW) in der Krankenhausnotaufnahme
[Adverse drug reactions (ADRs) in the hospital emergency room]. Dtsch Arztebl Int. 2018;115(15):251-8. German.

12.Rall M, Manser T, Guggenberger H, Gaba DM, Unertl K. Patientensicherheit und Fehler in der Medizin
[Patient safety and errors in medicine]. AINS. 2001;36(6):321-30. German.

13.Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9.

14.Frohnhofen H, Wehling M, Michalek C. Erste klinische Erfahrungen mit der neuen FORTA-Klassifikation
[First clinical experiences with the new FORTA classification]. Z Fur Gerontol Und Geriatr. 2012;45:21. German.

15.Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007;24(1):14-9.

16.Van den Akker M, Buntinx F, Metsemakers JF, Knottnerus JA. Marginal impact of psychosocial factors on multimorbidity: results of an explorative nested case-control study. Soc Sci Med. 2000;50(12):1679-93.

17.Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol. 2001;54(7):680-6.

18.Deutsche Gesellschaft für Geriatrie (DGG). Onlinepräsenz der Deutschen Gesellschaft für Geriatrie
[Online presence of the German Society for Geriatrics]. Available from: https://www.dggeriatrie.de/. Accessed on 27 Sep 2022. German.

19.Google. Scholar-Google. Available online: https://scholar.google.de. Accessed on 23 Feb 2021.

20.Amann U, Schmedt N, Garbe E. Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS list. Dtsch Arztebl Int. 2012;109(5):69-75.

21.Thiem U. Potenziell inadäquate Medikation
[Potentially inappropriate medication]. Der Internist. 2012;53(11):1125-30. German.

22.Holt S, Schmiedel S, Thürmann PA. Potenziell inadäquate Medikation für ältere Menschen
[Potentially inappropriate medication for older people]. Dtsch Arztebl Int. 2010;107(11):543-51. German.

23.Siebert S, Elkeles B, Hempel G, Kruse J, Smollich M. Die PRISCUS-Liste im klinischen Test. Praktikabilität und Vergleich mit internationalen PIM-Listen
[The PRISCUS list in clinical trials: Practicability and comparison with international PIM lists]. Z für Gerontol Und Geriatr. 2013;46(1):35-47. German.

24.Wehling M, Pazan F, Weiß C. FORTA Liste 2015. Drugs Aging. 2016;33(6):447-9.

25.Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(22):3898-944.

26.Frohnhofen H, Michalek C, Wehling M. Bewertung von Medikamenten in der Geriatrie mit der neuen FORTA-Klassifikation
[Evaluation of medications in geriatrics using the new FORTA classification]. Dtsch Med Wochenschr. 2011;136(19):1417-21. German.

27.Wehling M. Mehr Sicherheit durch FORTA. Was Sie alten Patienten verordnen dürfen und was nicht
[Greater safety with FORTA. What you can and cannot prescribe to elderly patients]. MMW Fortschr der Med. 2009;151(1):17. German.

28.Wehling M. Multimorbidity and polypharmacy. J Am Geriatr Soc. 2009;57(4):560-1.

29.Chalmers BP, Weston JT, Osmon DR, Hanssen AD, Berry DJ, Abdel MP. Prior hip or knee prosthetic joint infection in another joint increases risk three-fold of prosthetic joint infection after primary total knee arthroplasty: A matched control study. Bone Jt J. 2019;101:91-7.

30.Kheir MM, Tan TL, George J, Higuera CA, Maltenfort MG, Parvizi J. Development and evaluation of a prognostic calculator for the surgical treatment of periprosthetic joint infection. J Arthroplast. 2018;33(9):2986-92.e1.

31.Malik AT, Li M, Scharschmidt TJ, Khan SN. Revision of an infected total hip arthroplasty: the need for the adjustment of risk in bundled payment models for revision arthroplasty. Bone Jt J. 2019;101(5):547-51.

32.Grimberg A, Jansson V, Melsheimer O. Jahresbericht 2019
[Annual Report 2019]. Berlin (Germany): EPRD Deutsches Endoprothesenregister; 2019. German.

33.Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-6.

34.Behrends M, DePalma G, Sands L, Leung J. Association between intraoperative blood transfusions and early postoperative delirium in older adults. J Am Geriatr Soc. 2013;61(3):365-70.

35.Celis-Rodríguez E, Birchenall C, de La Cal MÁ, Castorena Arellano G, Hernández A, Ceraso D, et al. Clinical practice guidelines for evidence-based management of sedoanalgesia in critically ill adult patients. Med Intensiva. 2013;37(8):519-74.

36.Denny DL, Such TL. Exploration of relationships between postoperative pain and subsyndromal delirium in older adults. Nurs Res. 2018;67(6):421-9.

37.Holly C. Primary prevention to maintain cognition and prevent acute delirium following orthopaedic surgery. Orthop Nurs. 2019;38(4):244-50.

38.Kiely DK, Marcantonio ER, Inouye SK, Shaffer ML, Bergmann MA, Yang FM, et al. Persistent delirium predicts greater mortality. J Am Geriatr Soc. 2009;57(1):55-61.

39.Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin. S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin 2015
[S3 Guideline on Analgesia, Sedation, and Delirium Management in Intensive Care Medicine 2015]. Available from: https://www.awmf.org/uploads/tx_szleitlinien/001-012l_S3_Analgesie-Sedierung-Delirmanagement-in-der-Intensivmedizin-DAS_2021-08.pdf. Accessed on 28 Sep 2022. German.

40.Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med. 2004;164(18):1957-9.

41.Giebelstein, C. Praxisüberprüfung des Bewertungssystems “Fit for the Aged” (FORTA) in einer Klinik für Geriatrie
[Practical evaluation of the “Fit for the Aged” (FORTA) assessment system in a geriatric clinic]
[dissertation]. Lübeck (Germany): Universität zu Lübeck; 2015. German.

42.Pugh MJV, Rosen AK, Montez-Rath M, Amuan ME, Fincke BG, Burk M, et al. Potentially inappropriate prescribing for the elderly: effects of geriatric care at the patient and health care system level. Med Care. 2008;46(2):167-73.

43.Hoffmeister HM, Bode C, Darius H, Huber K, Rybak K, Silber S. Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen
[Interruption of antithrombotic treatment (bridging) in cardiac diseases]. Kardiologe. 2010;4(6):365-74. German.

44.Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J. 2018;198:135-44.

45.Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46.

46.Marx N, Frantz S, Gitt AK, Zirlik A. Kommentar zu den Leitlinien (2019) der European Society of Cardiology (ESC) zu “Diabetes, Prädiabetes und kardiovaskuläre Erkrankungen”
[Commentary on the 2019 guidelines of the European Society of Cardiology (ESC) on “Diabetes, Prediabetes, and Cardiovascular Diseases”]. Kardiologe. 2020;14(3):162-7. German.

47.Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140.

48.Hofmann W. Benzodiazepine in der Geriatrie. CME. 2014;11(1):49-55.

49.Siafarikas NI, Preuss U. Delir bei Demenz
[Delirium in dementia]. Fortschr Der Neurol Psychiatr. 2014;82(9):492-501. German.

50.Hshieh TT, Inouye SK, Oh ES. Delirium in the elderly. Psychiatr Clin North Am. 2018;41(1):1-17.

引用本文

Marcel Hoellger,Michael Kehrer,Dieter Christian Wirtz,Hendrik Kohlhof*. Optimizing Drug Therapy Safety of Geriatric Orthopedic Patients by Providing Integrated Geriatric Care [J]. Advances in Geriatric Medicine and Research. 2025; 7; (1). - .

文献评论

相关学者

相关机构